Bavarian Nordic A/S — Federal Contractor Profile

Contractor Overview

Total Contract Value: $951,139,353,453 ($951.1B)

Total Awards: 906

Company Profile

BAVARIAN NORDIC A/S is a Danish medical technology company with a significant presence in the federal government market, primarily through its contract work with the U.S. Department of Defense (DoD) and other agencies. The company specializes in medical devices, particularly in the areas of orthopedics, infectious diseases, and vaccines. BAVARIAN NORDIC A/S has a long history of providing critical medical supplies and services to the U.S. government, with a total contract value of $951.14 billion and 906 contracts awarded. The company's average contract size is $1,04,98,22,686, indicating the scale and importance of its work. Notably, BAVARIAN NORDIC A/S has not engaged in any sole-source contracts, suggesting a strong reliance on competitive bidding processes. The company's track record includes significant contracts such as the development and supply of the Jynneos vaccine, which is used to prevent smallpox and monkeypox. BAVARIAN NORDIC A/S's business strategy appears to be centered on maintaining a strong presence in the defense and public health sectors, leveraging its expertise in medical technologies to secure contracts. The company's performance history and contract patterns suggest a stable and expanding business trajectory, with a focus on maintaining and growing its client base within the federal government.

Specializations

• Orthopedic Devices
• Infectious Disease Vaccines
• Medical Supplies
• Smallpox and Monkeypox Vaccines
• Biodefense Technologies

Contractor Metrics

Average Contract Size: $0

Competitive Win Rate: 100%

Agency Concentration: moderate

Growth Trajectory: expanding

Sole Source Rate: 0%

Recompete Rate: 99%

Competitive Position

BAVARIAN NORDIC A/S is a niche specialist in the medical technology sector, particularly in the areas of orthopedics and infectious disease vaccines. The company's strong performance in securing competitive contracts and its focus on biodefense technologies position it as a key player in the federal government market. Its lack of sole-source contracts and high recompete rate indicate a robust competitive position and a strong track record of delivering high-quality products and services.

Value to Taxpayers

BAVARIAN NORDIC A/S provides significant value to taxpayers through its critical medical supplies and services, particularly in the areas of orthopedics and infectious disease vaccines. The company's average contract size of $1,04,98,22,686 and its focus on high-demand medical technologies suggest that it is well-positioned to deliver high-quality products and services. However, the lack of sole-source contracts and the high recompete rate indicate that the company is subject to competitive pressures, which may help ensure that taxpayers receive good value for their money.

Agency Relationships

BAVARIAN NORDIC A/S has a moderate concentration of clients within the federal government, with a significant presence in the Department of Defense (DoD) and the Department of Health and Human Services (HHS). The company's strong relationship with the DoD is particularly noteworthy, given the critical nature of its work in biodefense and medical supplies. While the company's reliance on the DoD and HHS is not a significant risk, the concentration of its client base within these agencies does raise concerns about potential dependency and the potential impact of changes in government priorities or funding.

Red Flags

• No sole-source contracts: While this may indicate a strong competitive position, it also means the company is not leveraging its expertise to secure exclusive contracts, which could limit its ability to secure larger, more lucrative contracts.
• High recompete rate: The high recompete rate suggests that the company is not consistently delivering exceptional value, which could be a concern for taxpayers.
• Moderate agency concentration: The company's reliance on a few key agencies could pose a risk if these agencies experience budget cuts or changes in priorities.

Green Flags

• Strong competitive position: BAVARIAN NORDIC A/S has a 100% competitive win rate, indicating that it is well-positioned to secure contracts through competitive bidding processes.
• Diverse product offerings: The company's focus on orthopedics, infectious disease vaccines, and biodefense technologies suggests a diverse portfolio of products and services, which could help mitigate risks associated with changes in government priorities.
• Consistent performance: The company's track record of delivering high-quality products and services, as evidenced by its significant contracts, suggests a strong performance history.

Key Contracts

BAVARIAN NORDIC A/S has secured several significant contracts, including the development and supply of the Jynneos vaccine, which is used to prevent smallpox and monkeypox. This contract, worth over $1 billion, highlights the company's expertise in infectious disease vaccines and its ability to deliver critical medical supplies to the federal government. The company's work on the Jynneos vaccine is particularly noteworthy, as it demonstrates its commitment to biodefense and public health. Additionally, BAVARIAN NORDIC A/S has secured contracts for the development and supply of orthopedic devices, which are critical for military personnel and other government employees. These contracts, while smaller in scale, demonstrate the company's ability to deliver high-quality medical supplies and services to the federal government. Overall, these contracts reveal BAVARIAN NORDIC A/S's strong capabilities in medical technologies and its strategic focus on biodefense and public health.

Frequently Asked Questions

Recent Federal Contracts

Bavarian Nordic A/S has 5 federal contracts on record. Below are the largest awards:

Related Pages